Repligen Corporation (RGEN) News
Filter RGEN News Items
RGEN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RGEN News Highlights
- For RGEN, its 30 day story count is now at 4.
- Over the past 12 days, the trend for RGEN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- DEC are the most mentioned tickers in articles about RGEN.
Latest RGEN News From Around the Web
Below are the latest news stories about REPLIGEN CORP that investors may wish to consider to help them evaluate RGEN as an investment opportunity.
Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare ConferenceWALTHAM, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at the 42nd Annual J.P. Morgan Healthcare conference being held January 8-11 in San Francisco. Tony J. Hunt, Chief Executive Officer, will present an overview of the company on Tuesday, January 9, 2024, at 2:15 p.m. PST. A live webcast of the presentation will be accessible through Repligen’s Investor Re |
Here’s Why Repligen Corporation (RGEN) Rose 13% in Q3TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” third-quarter investor letter. A copy of the same can be downloaded here. In the third quarter, the strategy outperformed the Russell Midcap Growth Index and returned -4.11% (net) while the index return was -5.22%. The third quarter saw a decline in […] |
Repligen's (NASDAQ:RGEN) investors will be pleased with their impressive 158% return over the last five yearsWhen you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose... |
Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription AgreementsWALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 0.375% Convertible Senior Notes due 2024 (the “2024 Notes”) and certain new investors, pursuant to which Repligen will issue $600 million aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the “New Notes”). Approximately $309.9 million |
Why Is Exact Sciences (EXAS) Up 2.5% Since Last Earnings Report?Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Repligen (RGEN) Up 21.3% Since Last Earnings Report: Can It Continue?Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Does Repligen Corp. (RGEN) Have a Bright Future?Conestoga Capital Advisors, an asset management company, released its “SMid Cap Growth Strategy” third-quarter 2023 investor letter. A copy of the same can be downloaded here. The Conestoga Smid Cap Growth Composite returned -6.36% net of fees in the third quarter, compared to the Russell 2500 Growth Index’s -6.84% return. Stock selection in the Industrials, Health […] |
UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability ReportWALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures. Themed “Making an Impact”, the report highlights the company’s measurable progress across multiple environmental, social and governance (ESG) initiatives since its inaugural 2020 Sustainability Report, “Committed to Making a Di |
Repligen Announces Publication of the Company’s 2022 Sustainability ReportWALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures. Themed “Making an Impact”, the report highlights the company’s measurable progress across multiple environmental, social and governance (ESG) initiatives since its inaugural 2020 Sustainability Report, “Committed to Making a Di |
Repligen Corporation to Present at Upcoming Investor ConferencesWALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at two upcoming investor conferences. Stifel 2023 Healthcare Conference being held November 14-15 in New York City. Tony J. Hunt, Chief Executive Officer, will participate in an analyst-led discussion on Wednesday, November 15, at 8:00 a.m. ET.Stephens’ Annual Investment Conference being held Novem |